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What's already known about this topic? 
 Empirical data on healthcare professionals’ (HCPs) and parents' experience with 
prenatal CMA are scarce.  
 Published data mainly focused on issues around uncertain results obtained via CMA, 
and on genetic health professionals. 
 The two main difficulties expressed by genetic counsellors associated with testing 
were interpreting uncertain results, and termination of pregnancies based on 
uncertain results 
What does this study add? 
 It is the first study examining attitudes of a wide range of professionals involved in 
CMA testing: laboratory professionals, fetal medicine experts and genetic health 
professionals.  
 We describe what types of results professionals think should or should not be 
disclosed and with whom they consider the onus for such decision making should lie.  
 These views are reflected in the recent UK guidelines about CMA testing. 
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Abstract 
Objectives: This study explored the views of healthcare-professionals (HCPs) in the UK about 
what information should be disclosed; when; and whether women/parents should be given 
a choice as to what they wish to know.  Methods: Q-methodology was used to assess the 
views of forty HCPs (genetic healthcare professionals, fetal medicine experts, lab-scientists). 
Results: Most participants agreed that variants of unknown clinical significance should not 
be disclosed. Participants were divided between those who considered variants of uncertain 
clinical significance helpful for parents and clinicians, and those who considered them 
harmful. Although recognising the potential disadvantages of disclosing risks for adult-onset 
conditions, participants thought it would be difficult to withhold such information once 
identified. Participants largely supported some parental involvement in determining which 
results should be returned.  Most participants believed that information obtained via CMA 
testing in pregnancy should either be disclosed during pregnancy, or not at all. Conclusion: 
HCPs taking part in the study largely believed that variants that will inform the management 
of the pregnancy, or are relevant to other family members, should be reported. Recent UK 
guidelines, published after this research was completed, reflect these opinions. 
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INTRODUCTION  
Chromosomal microarray analysis (CMA) allows the identification of small gains and losses 
of genetic material, not detected by conventional karyotyping. Because of its increased 
diagnostic yield, CMA is now the first-line genetic investigation for individuals with 
intellectual disability, developmental delay, autistic spectrum disorder, and multiple 
congenital anomalies.1,2 Although CMA has not yet replaced karyotyping in all indications for 
prenatal diagnosis (such as advanced maternal age or raised risk from biochemical tests), it 
is fast becoming the recommended test in pregnancies with structural anomalies, and 
increased nuchal translucency identified on ultrasound scan.3,4,5  This higher resolution view 
of the genome results in a greater chance of revealing: (1) variants of unknown clinical 
significance (e.g. novel microdeletions/duplications that contain no genes, or genes with  no 
known function); (2) variants with uncertain clinical significance (VOUS) (e.g. 
microdeletions/duplications which include genes with incomplete penetrance),5-8 (3) 
predisposition to diseases whose onset is not until adulthood (e.g. deletion of a cancer 
susceptibility gene),9 and  (4) findings relevant only to future pregnancies (e.g. a deletion of 
an x-linked gene in a female fetus).   
The findings generated by CMA raise ethical as well as practical questions. These include: to 
whom should testing be offered? (e.g. only in pregnancies where ultrasound anomalies are 
identified, or to all women?); which findings should be disclosed? (e.g. only those with clear 
pathogenicity, or also VOUS; childhood-onset conditions only or also adult-onset ones?); 
should women/parents be given a choice as to what type of results they receive?; and how 
can information about the fetus best be stored for potential future use? 
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Empirical data on healthcare professionals’ (HCPs') experience with prenatal CMA, and 
stakeholders’ views about these questions, are scarce. This is in part due to the, as yet, 
limited use of this technology in the prenatal setting. Focusing on the disclosure of uncertain 
results in pregnancy, Bernhardt et al10 explored the experiences of genetic counsellors in the 
United States. They demonstrated that about 40% of respondents were uncomfortable 
providing counselling regarding VOUS and expressed an interest in additional education 
regarding VOUS. From a survey distributed to genetic counsellors in the United States and 
Canada, Mikhaelian et al11 found the two main difficulties associated with testing were 
interpreting uncertain results, and termination of pregnancies based on uncertain results. 
Using a survey distributed to genetic counsellors in the United States, Walser et al have 
recently showed that participants found it important to disclose all types of results from 
prenatal CMA, including risks for adult-onset conditions (treatable and non-treatable), 
carrier status and VOUS.12  
Our study set out to explore the views of HCPs about three main aspects of prenatal CMA 
testing: (1) what information should be disclosed to women/parents, (2) when should it be 
disclosed (i.e. during pregnancy, or later on in life), and (3) who should decide.  Whereas 
previous studies mainly concentrated on genetic counsellors and on VOUS, we wanted  to 
gain a broader understanding of the issues around such tests, and to include other 
professionals involved in offering women/parents CMA testing in pregnancy, analysing, 
interpreting, and communicating the test results. 
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METHODS 
We utilised Q-methodology, which incorporates both qualitative and quantitative analysis.13 
Q-methodology originated in psychology research,14 and has since spread to the medical 
sciences, such as exploring women’s and HCPS’ views about antenatal testing.15-18 In Q-
methodology, participants are given a set of pre-determined statements about the research 
topic, which they are asked to sort (typically on a board), according to their degree of 
agreement/disagreement with each item (see Fig 1). Instead of indicating the level of 
agreement/disagreement with each item separately (as is the case with Likert- style 
questionnaires), the sorting process asks each participant to prioritise the statements in 
relation to each other, often resulting in deeper engagement with the research questions. 
Qualitative data, in the form of participants’ oral comments made during the process, are 
also generated.  The completed sorting for each participant (called a Q-sort) is loaded onto a 
statistical software program designed for Q-methodology that looks for groups of 
participants who have rank ordered the statements in a similar fashion. For instance, if 
participants A,E ,Z had similar rank orders,  they would be grouped together. The software 
then merges together the Q-sorts of participants in each group to yield a ‘characteristic Q-
sort’ for each group, which serves as an interpretable ‘best-estimate’ of the way participants 
in each group have ranked-ordered the statements; each characteristic Q-sort then 
represents a different point of view.  The characteristic Q-sorts (rather than individual Q-
sorts of participants, which contain too many variables for feasible interpretation), together 
with comments voiced by participants, are used for interpretation.19   
The study protocol was approved by the University of Southampton, Faculty of Medicine 
Ethics Committee. 
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[Place Figure 1 about here] 
Development of the Statements 
We generated a list of statements based on a literature review, two open-ended interviews 
with a fetal-medicine expert and a consultant in medical genetics, and a focus group with six 
lab-scientists, all experienced with prenatal CMA. To clarify the wording of the statements, 
reduce duplications, and generate new statements, pilot meetings were conducted with four 
HCPs (three genetic counsellors and a consultant in medical genetics) and two social 
scientists. The final list consisted of 44 statements (see Table 2), which were printed onto 
individually numbered cards. Q-methodology considers between 40 and 80 statements an 
appropriate number.19 
Participants and data collection 
At the time of data collection, prenatal CMA testing was carried out in the UK mainly via a 
research study (EACH),20 and as a purely clinical service by very few individual genetic 
centres, with no consensus or national guidelines. CMA was mainly offered in pregnancies 
with structural anomalies or increased nuchal translucency. National guidelines were issued 
well after the completion of the study.21 We wanted to explore the views of a range of HCPs 
and allied HCP (such as lab scientists involved in such testing) with at least some experience 
in prenatal CMA. We therefore recruited HCPs from centres either taking part in the EACH 
study, or where prenatal CMA was offered on a clinical basis. As DGW was part of the EACH 
study, she could provide the names of these centres as well as of fetal medicine experts 
familiar with CMA. Participants were recruited in one of three ways: (1) Invitation emails 
were sent to genetic-HCPs (gHCPs, i.e. medical geneticists, genetic counsellors, registrars) 
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and to lab-scientists who are involved in prenatal testing from the Wessex Clinical Genetics 
Service, to which SSR, DGW and AML belong (altogether  9 of 13 invited gHCPs, and all 4 
invited lab scientists  agreed to participate) (2) The study was presented to HCPs (mainly 
gHCPs) attending a national genetics meeting, Genethics Forum,22 in February 2014 (29 
gHCPs out of a total of 42 attendees). Participants were asked to provide their email address 
if interested in taking part. Six gHCPs agreed to take part, and meetings were arranged with 
four of them (3) Invitation emails were sent to the heads of five genetic laboratories of 
centres offering prenatal CMA testing all of whom agreed to participate; and to 17 fetal-
medicine experts, of whom nine agreed to participate. Participants were asked to provide 
the contact details of other colleagues who might be interested in taking part, who were 
then approached (sixteen, of whom thirteen agreed to participate). The recommended 
number of participants in Q-methodology studies is between 40 and 60 individuals.19 
Altogether, 45 of the 60 HCPs (75%) who were contacted by email agreed to take part. Two 
participants cancelled on the day of the meeting, and three did not complete the sorting 
process and were excluded from analysis. Forty sorting-configurations from participants 
belonging to nine centres in England and Scotland were analysed. Participants’ professional 
background, gender, and years of experience are detailed in Table 1. In total, participants 
included nineteen gHCPs, twelve lab scientists and nine fetal-medicine experts. 
Data collection took place between November 2013 and April 2014. Meetings lasted on 
average 60 minutes and took place mainly at participants’ work places. The meetings were 
audio-recorded with the consent of participants, and the completed Q-sort for each 
participant was noted. Participants’ comments were transcribed verbatim. 
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Data Analysis 
The statistical software program PQmethod version 2.35 was used for analysis, as described 
above. 
[Place Table 1 about here] 
RESULTS 
Q-methodology statistical software explored participants' Q-sorts, and grouped together 
those who had ranked statements in a similar way. Four groups resulted. See Table 2 for the 
four characteristic Q-sorts. Descriptions of each group's viewpoints are presented in Table 3. 
[Place Table 3 about here] 
 We now discuss the issues that were largely agreed upon by participants across all four 
groups, and those that created the most discussion or argument.  
To Disclose or not to Disclose, That is the Question 
It was generally agreed by participants from all four groups that findings of unknown clinical 
significance should not be included in laboratory reports and should not be disclosed to 
parents (see statements 9 and 19, Table 2).  There was also agreement that information that 
might be relevant to future pregnancies, even if not relevant to the current pregnancy, 
should be communicated (statement 23). 
As for disclosing VOUS, participants were largely against such disclosure (statement 22). 
Those who objected to the disclosure of VOUS (mainly those from group one, who generally 
thought disclosure should be for medical benefit only, and the majority of whom were lab 
scientists) agreed with the statement that disclosure of VOUS may lead to parental anxiety 
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(statement 33). Another downside of such disclosure is the termination of healthy 
pregnancies (statements 34). As described by one participant, this is a "lose/lose situation 
for parents"(#25, lab-scientist), as they either continue the pregnancy with worry that VOUS 
implies pathology, or terminate, unsure whether the fetus was indeed affected.   
Participants who supported the disclosure of VOUS voiced a range of reasons for their 
support: (1) it would be paternalistic not to disclose such findings and to assume that  
people cannot cope with uncertainty; (2) non-disclosure could not be justified if a child is 
born with a condition that is later shown to be associated with the un-disclosed information; 
and (3) when a microdeletion/duplication that might be pathogenic is identified together 
with a scan abnormality, it could assist women’s choices regarding the pregnancy: 
“given that women can access termination of pregnancy very easily for social reasons, I’m 
not sure that we should be playing God here and saying you can or can’t have a termination 
when your baby not only has a structural problem, but also a microdeletion, which may have 
implications for future life” (#32, fetal-medicine expert). 
With regards to disclosing adult-onset conditions in pregnancy, participants across all groups 
largely recognised that doing so could have harmful consequences.   These included an 
adverse impact on the quality of life of the child once born and on parents’ interaction with 
their child; removing the child’s ability to decide when they are older if and when to be 
tested; and discrimination against the child (statements 31, 32, 35, 36). Nevertheless, there 
was generally no objection to disclosing adult-onset conditions in pregnancy, especially if the 
conditions were medically actionable albeit not for many years (statements 20, 21, 44). In 
their comments, participants acknowledged that disclosing medically actionable conditions 
could benefit the child in two ways: s/he would not miss out on future intervention; and 
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her/his parents could be followed-up, which in turn also benefits the child, as s/he will not 
lose a parent to a preventable disease. As for non-actionable conditions, those who 
commented in favour of disclosing them thought that receiving the information in pregnancy 
could give parents a choice to terminate. Participants generally thought that it should only 
be offered to high-risk pregnancies, and not as a first-tier test for all women undergoing 
prenatal diagnosis (statements 37, 38). 
Who Decides? 
Participants across all groups disagreed with the idea that any decision about what 
information to disclose should be left to HCPs without parental involvement (statements 1, 
5, 16). However, most participants disagreed that personal preferences of parents, rather 
than expert opinions of clinicians, should determine which results are returned (statement 
26). Additionally, participants either agreed that it is a clinician's duty to disclose unexpected 
findings with evidence-based interventions, regardless of parental wishes, or were 
unsure/had no firm opinion about it (statement 40).  
Interestingly, participants were divided between those who thought that with good pre-test 
counselling, parents should be able to understand and make informed decisions, and those 
who believed that even with counselling it would be difficult for parents to understand the 
complexities around CMA (statements 2-4). For example: 
“it can be difficult for them [women/parents] to take in a lot of information, but with careful 
counselling, which is what we all aim to do, I think that most parents are able to take on-
board the subtleties of testing and to make decisions” (#10, gHCP)  
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“at the end of the day this is going to be an obstetrician consenting these women, in a busy 
antenatal clinic, she’s going to be really distressed and not listening to a word…you can’t 
possibly go through all the possible outcomes in that session” (#31,gHCP) 
The majority of participants (especially those belonging to group four, who were a mix of 
professionals) wanted (inter)national guidance about which findings should be disclosed 
(statements 18, 24, 25). As expressed by a few participants, a national panel of experts was 
considered helpful during the introduction of CMA into clinical use. Once CMA is offered as a 
clinical service to large numbers of pregnant women, such a need would wane with 
increasing experience.  Two practical suggestions were raised by participants to improve the 
process of prenatal CMA testing: providing women/parents with videos and other 
multimedia devices prior to the consultation; and educating clinicians involved in prenatal 
CMA testing.  
When? 
Most participants believed that information obtained via CMA testing in pregnancy should 
either be disclosed during pregnancy, or not at all. If choice was given to parents about what 
they wish to know, they could change their mind during pregnancy, but not after birth 
(statements 28-30).  
Although there were no statements about the possibility of storing information on fetuses 
and disclosing it later on in life, when it has clinical significance (e.g. adult-onset conditions), 
such issues were discussed by many of the participants. Participants generally disagreed 
with the notion of storing information until the onset of clinical significance, but for different 
reasons. Some participants cited potential litigation on the grounds of withholding life-
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saving information. Others thought parents would lose trust in the doctor-patient 
relationship. Some participants thought that re-contacting and disclosing information at a 
later stage was a good idea in principle, but thought that the practicalities were currently 
insurmountable: 
“Apart from anything else, how do you give it [adult-onset conditions] to them? it’s not like 
you can suddenly re-contact that family when the child is eighteen and say, oh, by the way 
we found this out when you were in utero and this might be useful for you now” (#10, gHCP) 
[Place Table 2 about here] 
Looking at participants’ professional background, two main differences stood out. First, lab-
scientists were more worried than others about adverse implications of disclosing late-onset 
conditions and VOUS. Second, gHCPs recognised the difficulties in preparing parents for the 
possible outcomes from prenatal CMA, yet were more likely than other professionals to 
believe that parents should take an active role in deciding what information to receive. 
DISCUSSION 
This study explored the views of HCPs involved in prenatal CMA in the UK, as it moves from 
being a research technique to being offered to a growing number of pregnant women as 
part of their clinical care. In deciding which results should be disclosed or not, most 
participants agreed that variants of unknown clinical significance should not be disclosed, 
but that findings with proximate clinical significance should be disclosed. However, in 
between these two extremes, benefit and harm were perceived in different ways by 
participants regarding the disclosure of VOUS. Bernhardt et al23 showed that some women 
given VOUS continued to worry after delivery and had regrets about having the test, which 
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matches the concerns that some of our participants expressed.  Van der steen et al24 showed 
94% of pregnant couples at increased risk of aneuploidies in pregnancy who opted for 
invasive prenatal diagnosis, who were given choice between a high and a low-resolution 
CMA test, chose testing at high-resolution, although being informed in advance that this 
would increase the likelihood of identifying VOUS. Eighty-four percent of them wished to be 
told of susceptibility loci for neurodevelopmental disorders (defined to participants as ‘risk 
factors’; genetic variants that are found in both healthy and affected individuals, with 
variable expression). When asked about their decision four weeks following results, 90% was 
satisfied with their choice, yet 19% of these were worried about the possible consequences 
of their decision. Importantly, none of the participants in this study were found to have a 
susceptibility locus in their fetus. In the recent UK guidelines, it has been recommended that 
VOUS that cannot be linked to a potential phenotype on the basis of genes involved, and low 
penetrance neuro-susceptibility loci should not be reported.21 
As for disclosing adult-onset conditions, although our participants acknowledged the 
disadvantages of disclosing such findings in pregnancy (for the same reasons that 
international guidelines almost unanimously recommend against testing in childhood), they 
also thought that it would be difficult to withhold this type of information once identified. 
This is in-line with the new UK guidelines, according to which variants that inform proximate 
management of other family members should be disclosed, on the basis of considering the 
benefit of the child.21 
Very limited data exist on parent preferences regarding adult-onset conditions in pregnancy 
identified incidentally (i.e. not the reason for testing). Srebniak et al25 showed that about 
55% of parents undergoing prenatal CMA testing wanted to be informed of adult-onset 
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conditions found incidentally. Kalynchuk et al26 and Walser et al12 showed that patients 
undergoing prenatal CMA found it important to know about adult-onset conditions, both 
treatable and non-treatable. Nevertheless, the majority of the participants in Kalynchuk et 
al’s study believed that the identification of an increased risk for adult-onset and/or a VOUS 
would cause them anxiety.26  
Some participants in our study recognised the difficulty of communicating the complexity 
around potential CMA findings to parents prior to testing. Others have demonstrated that 
the majority of participants in their studies did not recall being told, prior to testing, about 
the possibility of finding VOUS.23,27 Van der steen et al24 showed that 79% of pregnant 
couples wished to decide themselves about the resolution of the test and the type of 
findings they wish to receive. Even if ways are found to assure a satisfactory pre-test 
preparation and understanding of potential results, issues remain about how laboratories 
might filter or blind certain results and/or not record them in patients’ records. Although 
most participants thought that parents should be involved to some extent in deciding what 
information they wished to have, they also thought that national guidelines and consensus 
about general approaches would be valuable in part because too much choice for parents 
about multiple different outcomes was considered by many to create a space where 
informed decision making would be difficult to achieve. To date, various national approaches 
to prenatal genomic tests have been suggested:28 In their recent recommendations, the 
American College of Obstetrics and Gynaecology recommended that all findings, with and 
without known pathogenicity, and regardless of the age of onset, are reported.29 Other 
countries, especially in Europe, support a more restricted disclosure, often with the 
assistance of an advisory committee for complex findings, and whilst giving at least some 
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choice to parents to decide what results they wish to receive.3,25,30 According to the new UK 
guidelines, and contrary to the opinion of some of our participants, the only choice given to 
women/parents is whether or not to have prenatal CMA, and no choice is given regarding 
which findings are disclosed.21 
At present, CMA is performed on invasively obtained fetal material, and mainly in 
pregnancies with ultrasound abnormalities. Based on the higher detection rates and a 
shorter turnaround time, it has been suggested that CMA becomes the first-line test in all 
women undergoing invasive tests (i.e. replacing karyotyping), for whatever reason.3,31,32  
Most of the studies exploring experiences of women undergoing CMA to date have been 
following the identification of abnormal findings on a scan and these are more likely to agree 
to CMA.  How women would react if this was not the case, is uncertain.  It has  been 
suggested that the risk of miscarriage is the main ‘gatekeeper’ to testing during pregnancy, 
since once informed of this risk, many women choose not to proceed with testing.23,27 Proof 
of concept whole genome sequencing diagnostics by means of non-invasive prenatal testing 
(NIPT) has already been done although not yet routinely available.33,34 Once CMA and other 
genomic tests can be performed without the risk of a miscarriage, more women/parents 
might request such tests.35 This, together with the spread of genetic medicine to 
mainstream specialities,36 means that more HCPs will be involved in the process of referring 
women to testing, analysing, interpreting and communicating results. Although professional 
guidelines in Europe and the US stress the importance of pre-test face-to-face genetic 
counselling, preferably by a gHCPs,37 this may be unrealistic when CMA becomes the first-
line test in all pregnancies, and especially if done via non-invasive tests. An ‘intermediate’ 
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approach has been suggested, in which only complex cases would be referred to a gHCPs to 
discuss CMA testing prior to testing.38  
This study has several limitations: in spite of a fairly high response rate (75%) and an 
adequate number of participants for the methodology used, HCPs taking part in this study 
may not represent the entire population of HCPs in the UK. In addition, our results may be 
prone to respondent bias, as many of the participants were self-selected. The number of 
sorting configurations analysed was within, albeit at the lower limit, of the recommended 
number. 
CONCLUSION 
Much like the recommendations issued recently in the UK, participants taking part in this 
study largely believed that disclosure of findings obtained via CMA should be based on their 
present and future clinical consequence for that child, or other family members.   
Empirical data are highly desired on (1) how VOUS and predictions about adult-onset 
conditions affect parental choice regarding termination of pregnancy; (2) how  such 
information affects parents and their future child’s quality of life and interactions within the 
family; and (3) how and when adult-onset conditions are communicated to the child.  
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Figure 1: the Q sorting grid and a completed Q-sort from one of the participants.  
The numbers in the boxes represent the statements (see Table 2  for the numbered list of 
statements). In position (+4) are statements that participants most strongly agree with (in 
this example, statements 14, 6). In position (-4) are statements that participants most 
strongly disagree with (in this example, statements 30, 12). Position 0 is for statements that 
participants are unsure, or hold no firm opinions, about. Statements ranked at +1 to +3 are 
those that participants agreed with; those at -1 to -3 are those that they disagreed with, or 
agreed with less compared to statements ranked positively. 
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Table 1: Characteristics of Participants 
Characteristic 
Participants 
n (%) 
Professional background 
Genetic health professionals (gHCP): 
 Medical geneticist 
 Genetic counsellor 
 Registrar 
 
7 (18) 
9 (23) 
3 (8) 
Genetic laboratory scientist 12 (30) 
Fetal-medicine expert: 
 Fetal medicine midwives 
 Fetal medicine consultant 
 Obstetrician  
 
6 (15) 
2 (5) 
1 (2.5) 
Gender 
Female 32 (80) 
Male 8 (20) 
Years of experience 
1-5 11 (27.5%) 
6-10 9 (22.5%) 
>10 21 (52.5%) 
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Table 2: The four characteristic Q-sorts. 
Statement Group1 Group2 Group3 Group4 
 1. The decision about what information to 
disclose should be left to healthcare professionals 
and not involve the parents. 
-1 -4 -3 -1 
2. Pre-test discussion with parents about all 
possible outcomes is practically impossible. 
-2 -2 0 3 
3. Parents may find pre-test information about all 
possible outcomes hard to understand. 
1 -1 3 2 
4. Parents may perceive aCGH testing as risk-free, 
especially if describing it as an add-on test, and 
hence may not appreciate in advance its 
complexity. 
1 0 3 3 
5. Parents should take an active role in the 
decision making process about what information 
they wish to know. 
2 2 3 0 
6. The lab should report only findings that provide 
a clinical explanation for the presenting fetal 
abnormality. 
-3 -4 -2 1 
7. The lab should report all findings with a known 
clinical significance (either childhood or adult-
onset) 
0 4 -1 0 
8. The lab should report all findings with an onset 0 -3 0 1 
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in childhood (even if not relevant to the findings in 
pregnancy), but not adult-onset ones. 
9. The lab should report findings of unknown 
clinical significance.a 
-4 2 -2 -3 
10. Clinicians should have a panel of experts that 
they could consult with should they wish. 
3 2 2 4 
11. The lab should report findings of uncertain 
clinical significance (i.e. big range in penetrance).b 
-2 3 0 -2 
12. When the lab thinks that the information is 
complex, a genetic-health professional should be 
copied in to the report. 
4 3 1 4 
13. The lab should report all findings, apart from 
those known to have no clinical significance. 
-3 2 -2 0 
14. Preferably, it should be fetal-medicine experts 
that discuss aCGH testing with parents. 
-1 -3 -1 0 
15. Preferably, it should be genetic health 
professionals that discuss aCGH testing with 
parents. 
1 3 0 2 
16. The clinician who receives the report from the 
lab should decide what information to disclose to 
parents. 
-1 -2 -1 -4 
17. Clinicians should tailor the findings which they 
disclose depending on their assessment of what 
1 -1 0 -3 
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the parents want to know. 
18. Variants of unknowna/uncertainb clinical 
significance should be discussed by a national 
panel of experts to decide whether or not they 
should be disclosed to parents. 
1 0 1 1 
19.  Findings with unknowna medical significance 
should be disclosed to parents. 
-3 -1 -3 -2 
20. Medically actionable information, which is only 
relevant much later on in life, should be disclosed 
to parents. 
0 3 0 1 
21. Information about adult-onset conditions 
should be disclosed to parents only for conditions 
with medical intervention (such as cancer 
predisposition syndromes), but not for those with 
no medical intervention (such as 
neurodegenerative disorders). 
0 -2 -1 -1 
22.  Findings with uncertainb medical significance 
should be disclosed to parents (i.e. big range in 
penetrance). 
-2 1 -2 -2 
23. Information that could be relevant to future 
pregnancies should be disclosed, even if it’s not 
relevant to the present pregnancy (an X-linked 
condition, for instance, where the current fetus is 
3 4 2 2 
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a female). 
24. The decision of what information to disclose 
should be determined by National guidelines and 
not left to individual labs/clinicians. 
2 1 1 3 
25. Each case should be discussed separately. 
National guidelines may not be applicable to 
individual cases. 
-1 0 1 -1 
26. Personal preferences of parents should 
determine which results are returned, rather than 
expert opinions of clinicians. 
-1 -1 0 -1 
27. The possibility of litigation in the future should 
be taken into consideration while deciding what 
information to disclose to patients. 
0 -2 -2 -3 
28. Information about adult-onset conditions 
should not be disclosed during pregnancy, but 
after birth. 
-2 -3 -3 0 
29. Once parents decide not to be told a particular 
type of information, the decision cannot be 
changed. 
-3 -3 -4 -3 
30. Parents are allowed to change their 
preferences after giving birth and be informed 
about results that they wished not to know during 
pregnancy. 
-1 0 -1 -1 
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31. Information about adult-onset conditions may 
have an adverse impact on the future child’s 
quality of life. 
3 0 2 1 
32. Information about adult-onset conditions may 
have an adverse impact on parents’ interaction 
with their child. 
3 1 2 0 
33. Information about findings with 
uncertain/unknown clinical significance may lead 
to parental anxiety. 
3 1 4 3 
34. One reason why information about variants of 
unknowna/uncertainb clinical significance should 
not be disclosed to parents is that it may 
culminate in terminations of healthy pregnancies. 
2 -2 1 0 
35. Disclosing adult-onset conditions will remove 
the child’s ability to decide when they are older if 
they want to be tested, or not. 
4 1 4 3 
36. Information about adult-onset conditions may 
result in discrimination against the future child. 
2 0 3 0 
37. Prenatal aCGH testing should only be 
performed on high-risk pregnancies, but not on 
low-risk ones. 
2 1 3 2 
38. Prenatal aCGH testing should be offered to all 
pregnant women (even if for economic reasons- 
some will have to be paid for outside NHS). 
0 -3 -4 -3 
39. The decision about what information to -3 -1 -3 -2 
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disclose is no more difficult to make than 
traditional chromosomal analysis in pregnancy. 
40. It is the clinician’s duty to disclose unexpected 
findings with evidence-based interventions. 
0 2 0 2 
41. Disclosing incidental findingsc is no different 
from disclosing a chest mass identified through an 
x-ray that was carried out to check for pneumonia. 
-4 0 -1 -4 
42. One reason why incidental findingsc should be 
disclosed is that it gives parents a choice of 
terminating the pregnancy. 
0 0 2 1 
43.  One reason why variants of 
unknowna/uncertainb clinical significance should 
be disclosed is that it gives parents a choice of 
terminating the pregnancy. 
-2 -1 -3 -2 
44. Incidental findingsc should be disclosed to 
parents if it might benefit other family members 
(e.g. a deletion of a cancer susceptibility gene). 
1 3 1 -1 
aCGH (array Comparative-Genomic-Hybridization) 
a It was explained to participants that findings with unknown clinical significance are novel 
microdeletions/duplications that contain no known genes, or genes with no known function. 
b It was explained to participants that findings with uncertain clinical significance are 
microdeletions/duplications that contain known genes with incomplete penetrance.  
C It was explained to participants that incidental findings are those with known medical  
significance, yet not-related to the reason for which testing was carried out, either 
childhood, or adult-onset. 
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Table 3: description of the four viewpoints 
 
 
 
 
Group’s central 
message 
Characteristics of group 
Group 
#1 
Disclosing for medical 
benefit 
This group consisted of ten participants; three gHCPs, and seven lab 
scientists. They were: 
 In favour of disclosing findings which could be of medical benefit 
for the born child’s proximate or future health, and for her/his 
parents/other family members. 
 Against disclosing findings with an unknown, or uncertain medical 
significance, or with a known clinical significance yet no 
management. 
Group 
#2 
Disclosing a wide-range of 
findings 
This group consisted of ten participants; four gHCPs, three lab-scientists, 
and three fetal medicine experts. They were: 
 In favour of disclosing findings with definite or potential clinical 
significance, for either the present, or future pregnancies; and for 
both childhood and adult-onset conditions.  
 In favour of disclosing findings with uncertain clinical significance 
 Against giving parents choice as to what findings are disclosed 
Group 
#3 
Giving parents an active 
role in deciding what 
information to receive 
This group consisted of ten participants, the majority being gHCPs (eight); 
one lab-scientist; and one fetal-medicine-expert. 
 The main issue which distinguished this viewpoint from the others 
was the emphasis given to parents’ role in deciding whether or not 
they wish to be told of findings with uncertain clinical significance 
and of adult-onset conditions. 
Group 
#4 
A panel of experts or 
national guidelines to 
determine what findings 
are disclosed 
This group consisted of seven participants: three gHCPs; three fetal 
medicine experts; and one lab scientist. Participants sharing this viewpoint: 
 Were more in agreement with statements supporting a panel of 
experts and national guidelines to determine which findings are 
disclosed, compared to the other viewpoints.  
 Agreed less or disagreed with statements supporting an active role 
for parents, and those supporting the clinical judgement of 
clinicians in deciding what to disclose. 
 
